DSM N.V.

DSM N.V. (AMS:DSM) DSM en NOC*NSF zetten hun samenwerking als 'Partner in Sport' voort richting de Olympische Spelen in Londen 2012. De partners ondertekenden daartoe vandaag op Papendal een contract. Als innovatiepartner van NOC* NSF ondersteunt DSM het Nederlands Olympisch Team met nieuwe producten op het gebied van voeding en materialen om hiermee een bijdrage te leveren aan het behalen van topprestaties.

DSM N.V. (AMS:DSM) DSM and the Dutch Olympic Committee/Dutch Sports Federation (NOC*NSF) will continue to be 'Partners in Sports' in the run-up to the London 2012 Olympics. The partners have today signed an agreement to this effect at the Papendal Dutch National Sports Centre. As innovation partner of NOC*NSF, DSM is supporting the Dutch Olympic team with innovations in the field of nutrition and materials in order to help the team achieve top performances.

DSM N.V. (AMS:DSM) Royal DSM N.V., the global Life Sciences and Materials Sciences company today announced the execution of a multimillion dollar cooperative funding agreement with the US Department of Energy to underwrite a portion of research and development costs aimed at enabling "second generation" biofuels from non-food feedstocks.

DSM N.V. (AMS:DSM) Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, and the United Nations World Food Programme (WFP) announce that the 2008 ICIS Innovation Awards for Best Business Innovation has been awarded to DSM Nutritional Products and WFP for the MixMe (TM) micronutrient powder.

DSM N.V. (AMS:DSM) DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces that it has made an investment in the new business incubator in the field of medical devices Accelerated Technologies II, L.P. (ATP). The investment further strengthens DSM's position in the biomedical materials market, one of the Emerging Business Areas defined in its Vision 2010 - Building on Strengths strategy. Financial details will not be disclosed.

DSM N.V. (AMS:DSM) Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that DSM Anti-Infectives has decided to close its site in Strängnäs, Sweden. The site mainly produces clavulanic acid. Total cost of closure will be slightly above EUR 10 million (after tax) and will be reported as an exceptional item in Q4.

DSM N.V. (AMS:DSM) Major landmark in the 80 year history of Penicillin

DSM N.V. (AMS:DSM) DSM Venturing, the corporate venturing unit of Royal DSM N.V., today announces that it has made an equity investment in The Compliers Group International B.V. (TCG). The Netherlands-based company focuses on the development of smart pharmaceutical packaging solutions that contain microchips which enable the monitoring of a patient's therapy compliance. Financial details of the investment will not be disclosed.

DSM N.V. (AMS:DSM) Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, will update analysts and investors at its annual conference in Vaalsbroek on 25 and 26 September 2008 on the progress made in its Vision 2010 strategy. DSM is also updating its 2008 EBIT guidance today, from EUR 970 million, with potential upside, to EUR 1,025-1,075 million on the back of continued strength in some of DSM's businesses, particularly DSM Agro.

DSM N.V. (AMS:DSM) Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in The Netherlands, today announces that the second polymerization plant for Stanyl® polyamide 46 on the Chemelot site in Geleen (Netherlands) has opened. The new plant doubles DSM's worldwide production capacity for this high-performance plastic, supporting expected continuous strong growth in the coming years based on the leading position of Stanyl® in electronics and the growing usage in automotive applications due to higher demand for metal replacement. DSM has invested several tens of millions of euros in the new plant.